Putney continues winning streak with launch of generic chewable Rimadyl

Putney was founded in Portland, ME, in 2006 with the goal of developing a pipeline of 20 generic drugs for the veterinary market, and it's well on the way to moving those products to market. On Thursday, the company announced that it has launched an FDA-approved version of Zoetis' ($ZTS) popular Rimadyl (carprofen) chewable tablets to treat pain in pets. Putney is now the only company that can boast FDA approvals for generics of all three formulations of Rimadyl, which is also available in caplets and as an injectable solution. The chewable generic is Putney's ninth marketed product in animal health and its fourth FDA approval in the last three months. The company estimates that veterinarians will save about 30% on Putney's chewable carprofen over Zoetis' branded version. "Vets can feel free to pass on those savings to pet owners," Putney CEO Jean Hoffman tells FierceAnimalHealth. Release